tbuckley/cabot-search huggingface dataset:
Abstract 13068: Epsilon and Inverted T Waves in Right Side Precordial Leads in Pulmonary Hypertensive Patients With or Without Right Ventricular Hypertrophy or Fibrosis on Cardiac Computed Tomography
Authors: Nobusada FUNABASHI, Koya Ozawa, Yoshio Kobayashi
Journal: Circulation (2020)

Introduction: Epsilon and inverted T waves on V1-3 leads are known as specific ECG findings in patients with arrhythmogenic right ventricular (RV) cardiomyopathy (ARVC), which suggests the presence of RV conduction delay. Right bundle branch block (RBBB) is often observed in ARVC. In patients with pulmonary hypertension (PH) due to RV pressure load, the occurrence of RV hypertrophy and fibrosis are frequently observed, which may also lead to the occurrence of RV conduction delay and epsilon waves. Hypothesis: We hypothesized that there were epsilon and inverted T waves in right side precordial leads on ECG in PH patients with RV hypertrophy and/or RV fibrosis, both confirmed on cardiac CT. Methods: We retrospectively analyzed 43 patients (33 females, 55 ± 15 years, 31 chronic thromboembolic PH, 7 idiopathic pulmonary arterial hypertension) with proven PH by right heart catheterization. On CT, RV fibrosis was defined as a contrast defect in the early phase and a conversely abnormal enhancement in the late phase. Results: 32 and 9 patients had RV hypertrophy and RV fibrosis, respectively; of these, 4 had both. Of 32 PH patients with RV hypertrophy, 2 had complete RBBB and 8 had incomplete RBBB. Of 22 PH patients with RV hypertrophy but without any RBBB, only one (5%) had typical epsilon waves and 2 (9%) had waves with abnormal small upward spikes after the QRS wave that were more marked in II and aVF leads than V1 and 2 leads; these were not typical epsilon waves. 14 had a negative T wave in V1-3 leads (5 had only a V1 lead, one had only V1 and 2 leads, 4 had only V1-3 leads, and 4 had V1-4 leads, respectively). Of 9 PH patients with RV hypertrophy, one had complete RBBB and one had incomplete RBBB. Of 7 PH patients with RV fibrosis but without any RBBB, none (0%) had epsilon waves in V1-3 leads. All 7 had a negative T wave in V1-3 leads (3 had only a V1 lead, one had only V1 and 2 leads, 2 had only V1-3 leads, and one had V1-4 leads). Conclusions: In a total of 37 PH participants with an organized RV myocardial change, such as RV hypertrophy and fibrosis confirmed on cardiac CT, only one (3%) had typical epsilon waves that are frequently found in patients with ARVC. The mechanism of epsilon waves occurring predominantly in V1-3 leads seems not only to be caused by an organised RV myocardium, but also by other factors.
Dynamic α-Fetoprotein Response—Are We Ready to Change the Dynamics of Hepatocellular Carcinoma Liver Transplant Practice?
Authors: Chirag S. Desai, A. Sidney Barritt
Journal: JAMA Surgery (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study*
Authors: D.F. Murrell, A. Patsatsi, P. Stavropoulos, S. Baum, T. Zeeli, J.S. Kern, A.‐V. Roussaki‐Schulze, R. Sinclair, I.D. Bassukas, D. Thomas, A. Neale, P. Arora, F. Caux, V.P. Werth, S.G. Gourlay, P. Joly
Journal: British Journal of Dermatology (2021)

Bruton tyrosine kinase (BTK) inhibition targets B-cell and other non-T-cell immune cells implicated in the pathophysiology of pemphigus, an autoimmune disease driven by anti-desmoglein autoantibodies. Rilzabrutinib is a new reversible, covalent BTK inhibitor demonstrating preclinical efficacy as monotherapy in canine pemphigus foliaceus.To evaluate the efficacy and safety of oral rilzabrutinib in patients with pemphigus vulgaris in a multicentre, proof-of-concept, phase II trial.Patients with Pemphigus Disease Area Index severity scores 8-45 received 12 weeks of oral rilzabrutinib 400-600 mg twice daily and 12 weeks of follow-up. Patients initially received between 0 and ≤ 0·5 mg kg-1 prednisone-equivalent corticosteroid (CS; i.e. 'low dose'), tapered after control of disease activity (CDA; no new lesions, existing lesions healing). The primary endpoints were CDA within 4 weeks on zero-to-low-dose CS and safety.In total, 27 patients with pemphigus vulgaris were included: nine newly diagnosed (33%) and 18 relapsing (67%); 11 had moderate disease (41%) and 16 moderate to severe (59%). The primary endpoint, CDA, was achieved in 14 patients (52%, 95% confidence interval 32-71): 11 using low-dose CS and three using no CS. Over 12 weeks of treatment, mean CS doses reduced from 20·0 to 11·8 mg per day for newly diagnosed patients and from 10·3 to 7·8 mg per day for relapsing patients. Six patients (22%) achieved complete response by week 24, including four (15%) by week 12. Treatment-related adverse events were mostly mild (grade 1 or 2); one patient experienced grade 3 cellulitis.Rilzabrutinib alone, or with much lower CS doses than usual, was safe, with rapid clinical activity in pemphigus vulgaris. These data suggest that BTK inhibition may be a promising treatment strategy and support further investigation of rilzabrutinib for the treatment of pemphigus.
Abstract 15036: Chronic Disease Stigma, Skepticism of the Health System, and Socio-Economic Fragility: Factors Impacting Receptiveness to a Non-Communicable Disease Intervention in Rural Kenya
Authors: Rae Dong, Claudia Leung, Mackenzie Naert, Violet Naanyu, Peninah Kiptoo, Winnie Matelong, Esther Matini, Vitalis Orango, Gerald Bloomfield, David Edelman, Valentin Fuster, Simon Manyara, Diana Menya, Sonak D Pastakia, Thomas Valente, Jemima Kamano, Carol Horowitz, Rajesh Vedanthan
Journal: Circulation (2018)

Introduction: Non-communicable diseases (NCDs) are the leading cause of mortality in the world, with 80% of burden in low-and middle-income countries (LMICs). Studies have found microfinance (MF) p...
Increasing resolution in the mechanisms of resolve
Authors: Adam Bulley, Daniel L. Schacter
Journal: Behavioral and Brain Sciences (2021)

Ainslie offers an encompassing and compelling account of willpower, although his big-picture view comes occasionally at the cost of low resolution. We comment on ambiguity in the metacognitive and prospective mechanisms of resolve implicated in recursive self-prediction. We hope to show both the necessity and promise of specifying testable cognitive mechanisms of willpower.
SEPTAL MYECTOMY OR ALCOHOL ABLATION FOR HYPERTROPHIC CARDIOMYOPATHY: A NATIONWIDE INPATIENT SAMPLE (NIS) DATABASE ANALYSIS
Authors: Waqas Ullah, Nishanth Thalambedu, Salman Zahid, Sameer Saleem, Drew Johnson, Zain Ali, Donald Haas, Ihab Hamzeh, Yochai Birnbaum, Salim Virani, Mahboob Alam
Journal: Journal of the American College of Cardiology (2021)
Somatic Mutations Associated with Myeloid Transformation of RUNX1 -Mutated Familial Platelet Disorders with Propensity to Myeloid Malignancies Using Targeted Next-Generation Sequencing
Authors: Bruno K L Duarte, Samuel S Medina, Gabriela G Yamaguti Hayakawa, Fernando Ferreira Costa, Michael J. Rauh, Margareth C Ozelo
Journal: Blood (2017)
Inhibition of Jumonji Histone Demethylases Selectively Suppresses HER2+ Breast Leptomeningeal Carcinomatosis Growth via Inhibition of GMCSF Expression
Authors: Arunoday Bhan, Khairul I. Ansari, Mike Y. Chen, Rahul Jandial
Journal: Cancer Research (2021)

Abstract HER2+ breast leptomeningeal carcinomatosis (HER2+ LC) occurs when tumor cells spread to cerebrospinal fluid–containing leptomeninges surrounding the brain and spinal cord, a complication with a dire prognosis. HER2+ LC remains incurable, with few treatment options. Currently, much effort is devoted toward development of therapies that target mutations. However, targeting epigenetic or transcriptional states of HER2+ LC tumors might efficiently target HER2+ LC growth via inhibition of oncogenic signaling; this approach remains promising but is less explored. To test this possibility, we established primary HER2+ LC (Lepto) cell lines from nodular HER2+ LC tissues. These lines are phenotypically CD326+CD49f−, confirming that they are derived from HER2+ LC tumors, and express surface CD44+CD24−, a cancer stem cell (CSC) phenotype. Like CSCs, Lepto lines showed greater drug resistance and more aggressive behavior compared with other HER2+ breast cancer lines in vitro and in vivo. Interestingly, the three Lepto lines overexpressed Jumonji domain–containing histone lysine demethylases KDM4A/4C. Treatment with JIB04, a selective inhibitor of Jumonji demethylases, or genetic loss of function of KDM4A/4C induced apoptosis and cell-cycle arrest and reduced Lepto cell viability, tumorsphere formation, regrowth, and invasion in vitro. JIB04 treatment of patient-derived xenograft mouse models in vivo reduced HER2+ LC tumor growth and prolonged animal survival. Mechanistically, KDM4A/4C inhibition downregulated GMCSF expression and prevented GMCSF-dependent Lepto cell proliferation. Collectively, these results establish KDM4A/4C as a viable therapeutic target in HER2+ LC and spotlight the benefits of targeting the tumorigenic transcriptional network. Significance: HER2+ LC tumors overexpress KDM4A/4C and are sensitive to the Jumonji demethylase inhibitor JIB04, which reduces the viability of primary HER2+ LC cells and increases survival in mouse models.
TAKOTSUBO CARDIOMYOPATHY: A RARE COMPLICATION FOLLOWING PERCUTANEOUS MITRAL VALVE REPAIR
Authors: Shilla Zachariah, Oreoluwa Oladiran, Keerat Rai Ahuja, Charnjeet Sandhu, Rishin Handa, Murtaza Sundhu, Muhammad Ameen, Abigayle Sullivan, Nidrit Bohra, Anthony Licata
Journal: Journal of the American College of Cardiology (2021)
HEPATOCYTE GROWTH FACTOR AND PROGRESSION OF EXTRA-CORONARY CALCIFICATION IN THE MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS
Authors: Oluseye Ogunmoroti, Olatokunbo Osibogun, Richard Ferraro, Olumuyiwa Esuruoso, Paul Ndunda, Nicholas Larson, Paul Decker, Suzette Bielinski, Roger Blumenthal, Matthew Budoff, Erin Michos
Journal: Journal of the American College of Cardiology (2021)
SYNCOPE AND SUDDEN DEATH IN A PATIENT WITH SEVERE AORTIC STENOSIS DOCUMENTED BY ELECTROCARDIOGRAPHY
Authors: Bo Wang, Shane Prejean, Roberto Camacho, Thomas Watts, Hussein Abu Daya, Mustafa Ahmed, Fadi Hage, Navkaranbir Bajaj, Harish Doppalapudi, Ami Iskandrian
Journal: Journal of the American College of Cardiology (2021)
A PSGL-1 glycomimetic reduces thrombus burden without affecting hemostasis
Authors: Daniel J. Wong, Diane D. Park, Simon S. Park, Carolyn A. Haller, Jiaxuan Chen, Erbin Dai, Liying Liu, Appi R. Mandhapati, Pradheep Eradi, Bibek Dhakal, Walter J. Wever, Melinda Hanes, Lijun Sun, Richard D. Cummings, Elliot L. Chaikof
Journal: Blood (2021)
DNA damage repair promotion in colonic epithelial cells by andrographolide downregulated cGAS‒STING pathway activation and contributed to the relief of CPT-11-induced intestinal mucositis
Authors: Yuanyuan Wang, Bin Wei, Danping Wang, Jingjing Wu, Jianhua Gao, Haiqing Zhong, Yang Sun, Qiang Xu, Wen Liu, Yanhong Gu, Wenjie Guo
Journal: Acta Pharmaceutica Sinica B (2021)

Gastrointestinal mucositis is one of the most debilitating side effects of the chemotherapeutic agent irinotecan (CPT-11). Andrographolide, a natural bicyclic diterpenoid lactone, has been reported to possess anti-colitis activity. In this study, andrographolide treatment was found to significantly relieve CPT-11-induced colitis in tumor-bearing mice without decreasing the tumor suppression effect of CPT-11. CPT-11 causes DNA damage and the release of double-stranded DNA (dsDNA) from the intestine, leading to cyclic-GMP-AMP synthase (cGAS)‒stimulator of interferon genes (STING)-mediated colitis, which was significantly decreased by andrographolide both in vivo and in vitro. Mechanistic studies revealed that andrographolide could promote homologous recombination (HR) repair and downregulate dsDNA‒cGAS‒STING signaling and contribute to the improvement of CPT-11-induced gastrointestinal mucositis. These results suggest that andrographolide may be a novel agent to relieve gastrointestinal mucositis caused by CPT-11.
COMMISSURAL ALIGNMENT AFTER TRANSFEMORAL DELIVERY OF THE JENAVALVE TRANSCATHETER AORTIC VALVE
Authors: Nadira Hamid, Lauren Ranard, Omar Khalique, Rebecca Hahn, Tamim Nazif, Isaac George, Vivian Ng, Amisha Patel, Thomas Cahill, Shmuel Chen, Hussein Rahim, Anjali Sharma, Yaser Nemshah, Vinayak Bapat, Martin Leon, Susheel Kodali, Torsten Vahl
Journal: Journal of the American College of Cardiology (2021)
GENOTYPE-GUIDED P2Y12 INHIBITION FOLLOWING PCI BENEFITS CYP2C19 LOSS OF FUNCTION PATIENTS WITH NORMAL RENAL FUNCTION COMPARED TO THOSE WITH CHRONIC KIDNEY DISEASE
Authors: Roy Mathew, Mandeep Sidhu, Michael Farkouh, Charanjit Rihal, Ryan Lennon, Mohammad El-Hajjar, Neil Yager, Khaled Abdul-Nour, Steven Weitz, Deaglan O'Cochlain, Justin Levisay, Vishubhakta Murthy, John Graham, Vladimir Dzavik, Kevin Marzo, Derek So, Shaun Goodman, Naveen Pereira
Journal: Journal of the American College of Cardiology (2021)
Long-term structural and symptomatic effects of intra-articular sprifermin in patients with knee osteoarthritis: 5-year results from the FORWARD study
Authors: Felix Eckstein, Marc C Hochberg, Hans Guehring, Flavie Moreau, Victor Ona, Asger Reinstrup Bihlet, Inger Byrjalsen, Jeppe Ragnar Andersen, Benjamin Daelken, Oliver Guenther, Christoph Ladel, Martin Michaelis, Philip G Conaghan
Journal: Annals of the Rheumatic Diseases (2021)

The FORWARD (FGF-18 Osteoarthritis Randomized Trial with Administration of Repeated Doses) trial assessed efficacy and safety of the potential disease-modifying osteoarthritis drug (DMOAD) sprifermin in patients with knee osteoarthritis. Here, we report 5-year efficacy and safety results.Patients were randomised to intra-articular sprifermin 100 µg or 30 µg every 6 months (q6mo) or 12 months, or placebo, for 18 months. The primary analysis was at year 2, with follow-up at years 3, 4 and 5. Additional post hoc exploratory analyses were conducted in patients with baseline minimum radiographic joint space width 1.5-3.5 mm and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain 40-90, a subgroup at risk (SAR) of progression.378 (69%) patients completed the 5-year follow-up. A significant dose-response in total femorotibial joint cartilage thickness with sprifermin (trend test, p<0.001) and a 0.05 mm mean difference with sprifermin 100 µg q6mo versus placebo (95% CI 0.00 to 0.10; p=0.015) were sustained to year 5. WOMAC pain scores improved ~50% from baseline in all groups. No patient in the 100 µg q6mo group had replacement of the treated knee. 96%-98% of patients receiving sprifermin and 98% placebo reported adverse events, most were mild or moderate and deemed unrelated to treatment. Adverse event-related study withdrawals were <10%. Differentiation in WOMAC pain between sprifermin 100 µg q6mo and placebo in the SAR (n=161) at year 3 was maintained to year 5 (-10.08; 95% CI -25.68 to 5.53).In the longest DMOAD trial reported to date, sprifermin maintained long-term structural modification of articular cartilage over 3.5 years post-treatment. Potential translation to clinical benefit was observed in the SAR.NCT01919164.
Characteristics of Postmarketing Studies for Vaccines Approved by the US Food and Drug Administration, 2006-2020
Authors: Osman Moneer, ChangWon C. Lee, Jerry Avorn, Aaron S. Kesselheim
Journal: JAMA Network Open (2021)

This cross-sectional study uses data from the US Food and Drug Administration (FDA) to review the postmarketing requirements and commitments attached to new vaccines approved for use in the past 15 years in the United States.
TRANSTHYRETIN AMYLOIDOSIS IN ELDERLY: ARE THERE DIFFERENCES ACCORDING TO AGE?
Authors: Nahikari Salterain Gonzalez, Javier Ibero Valencia, Alvaro Riesgo Garcia, Aitor Hernandez Hernandez, Ines Diaz Dorronsoro, Ramon Lecumberri Villamediana, Juan Jose Gavira Gomez
Journal: Journal of the American College of Cardiology (2021)
Magnetic Drug Navigation: Magnetically Navigated Protein Transduction In Vivo using Iron Oxide‐Nanogel Chaperone Hybrid (Adv. Healthcare Mater. 9/2021)
Authors: Riku Kawasaki, Yoshihiro Sasaki, Tomoki Nishimura, Kiyofumi Katagiri, Kei‐ichi Morita, Yurina Sekine, Shin‐ichi Sawada, Sada‐atsu Mukai, Kazunari Akiyoshi
Journal: Advanced Healthcare Materials (2021)

In article number 2001988 by Yoshihiro Sasaki, Kazunari Akiyoshi, and co-workers, the magnetic nanogel chaperone, comprising of self-assembled polysaccharide nanogels and iron oxide nanoparticles, is developed for magnetically navigated in vivo protein transduction. Magnetic navigation enhances accumulation of the magnetic nanogel chaperone toward tumor tissues. Saporin-loaded magnetic nanogel chaperone exhibits excellent anti-tumor efficacy against oral cancer xenograft mice in vivo.
ARTIFICIAL INTELLIGENCE-ENHANCED ECG IDENTIFICATION OF PREVIOUSLY UNRECOGNIZED CARDIOVASCULAR DISEASES
Authors: Xiaoxi Yao, David Rushlow, Jonathan Inselman, Rozalina McCoy, Thomas Thacher, Emma Behnken, Matthew Bernard, Steven Rosas, Abdulla Akfaly, Fnu Artika, Paul Molling, Joseph Krien, Randy Foss, Barbara Barry, Konstantinos Siontis, Suraj Kapa, Patricia Pellikka, Francisco Lopez-Jimenez, Zachi Itzhak Attia, Nilay Shah, Paul Friedman, Peter Noseworthy
Journal: Journal of the American College of Cardiology (2021)
PREDICTION OF INCREASED CORONARY FLOW AFTER ELECTIVE REVASCULARIZATION BY PREPROCEDURAL CORONARY FLOW ASSESSMENT USING TRANSTHORACIC DOPPLER ECHOCARDIOGRAPHY
Authors: Tatsuhiro Nagamine, Yoshihisa Kanaji, Masahiro Hoshino, Tomoyo Sugiyama, Masao Yamaguchi, Masahiro Hada, Toru Misawa, Yumi Yasui, Tsunekazu Kakuta
Journal: Journal of the American College of Cardiology (2021)
PREDICTORS OF ANTICOAGULATION COMPLIANCE IN PATIENTS WITH PULMONARY EMBOLISM AFTER HOSPITAL ADMISSION
Authors: Karim Merchant, Parth Desai, Stephen Morris, Dalila Masic, Sovik DeSirkar, Nicolas Krepostman, Matthew Collins, Nathalie Antonios, Lucas Chan, Joshua Newman, Sorcha Allen, Ahmad Manshad, Shannon Kuhrau, Jawed Fareed, Ahmed Elkaryoni, Yevgeniy Brailovsky, Amir Darki
Journal: Journal of the American College of Cardiology (2021)
ECONOMIC IMPACT OF ANEMIA ON MYOCARDIAL INFARCTION HOSPITALIZATIONS: A NATIONAL DATABASE ANALYSIS
Authors: Aravdeep Jhand, Hyo Jung Tak, Arslan Ahmed, Eirini Apostolidou, S. Elissa Altin, Matthew Sherwood, Sunil Rao, Jeffrey Carson, Li-Wu Chen, J. Abbott, Andrew Goldsweig
Journal: Journal of the American College of Cardiology (2021)
EVOLOCUMAB USE IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS AND DYSLIPIDEMIA: FINAL RESULTS OF THE OPEN LABEL EXTENSION PERIOD (BEIJERINCK)
Authors: Franck Boccara, Bruno Caramelli, Alexandra Calmy, Princy Kumar, J. Antonio G. Lopez, Sarah Bray, Marcoli Cyrille, Robert Rosenson
Journal: Journal of the American College of Cardiology (2021)
Alcohol intake and cancer of the upper digestive tract (multiple letters) [14]
Authors: C. La Vecchia, S. Franceschi, A. Favero, R. Talamini, E. Negri, K. K. Cheng, C. Cummins, R. Maric, V. Reed, R. Fitzgerald, C. Caygill, M. Gronbaek, T. I A Sorensen
Journal: BMJ (1999)
DOES THE DURATION OF INTRA-AORTIC BALLOON PUMP OR PERCUTANEOUS DEVICE PRE-HEART TRANSPLANT IMPACT SURVIVAL?
Authors: Iulia Barbur, Matthew McGoldrick, Katherine Giuliano, Eric Etchill, Steven Hsu, Kavita Sharma, Ahmet Kilic, Chun Woo Choi
Journal: Journal of the American College of Cardiology (2021)
Sex Disparities in Enrollment in Recent Randomized Clinical Trials of Acute Stroke
Authors: Brent Strong, Julia Pudar, Amanda G. Thrift, Virginia J. Howard, Murtaza Hussain, Cheryl Carcel, Gustavo de los Campos, Mathew J. Reeves
Journal: JAMA Neurology (2021)

The underenrollment of women in randomized clinical trials represents a threat to the validity of the evidence supporting clinical guidelines and potential disparities in access to novel treatments.To determine whether women were underenrolled in contemporary randomized clinical trials of acute stroke therapies published in 9 major journals after accounting for their representation in underlying stroke populations.MEDLINE was searched for acute stroke therapeutic trials published between January 1, 2010, and June 11, 2020.Eligible articles reported the results of a phase 2 or 3 randomized clinical trial that enrolled patients with stroke and/or transient ischemic attack and examined a therapeutic intervention initiated within 1 month of onset.Data extraction was performed by 2 independent authors in duplicate. Individual trials were matched to estimates of the proportion of women in underlying stroke populations using the Global Burden of Disease database.The primary outcome was the enrollment disparity difference (EDD), the absolute difference between the proportion of trial participants who were women and the proportion of strokes in the underlying disease populations that occurred in women. Random-effects meta-analyses of the EDD were performed, and multivariable metaregression was used to explore the associations of trial eligibility criteria with disparity estimates.The search returned 1529 results, and 115 trials (7.5%) met inclusion criteria. Of 121 105 randomized patients for whom sex was reported, 52 522 (43.4%) were women. The random-effects summary EDD was -0.053 (95% CI, -0.065 to -0.040), indicating that women were underenrolled by 5.3 percentage points. This disparity persisted across virtually all geographic regions, intervention types, and stroke types, apart from subarachnoid hemorrhage (0.117 [95% CI, 0.084 to 0.150]). When subarachnoid hemorrhage trials were excluded, the summary EDD was -0.067 (95% CI, -0.078 to -0.057). In the multivariable metaregression analysis, an upper age limit of 80 years as an eligibility criterion was associated with a 6-percentage point decrease in the enrollment of women.Further research is needed to understand the causes of the underenrollment of women in acute stroke trials. However, to maximize representation, investigators should avoid imposing age limits on enrollment.
USE OF COMMERCIAL CLAIMS DATA TO ESTIMATE TRANSTHYRETIN-AMYLOID CARDIOMYOPATHY PREVALENCE AND INCIDENCE IN THE US
Authors: Duncan Brown, Montserrat Vera-Llonch, Jose Tomas Ortiz Perez, Sheila R. Reddy, Eunice Chang, Marian H. Tarbox, Jose Nativi-Nicolau, Nowell Fine
Journal: Journal of the American College of Cardiology (2021)